ENTYVIO
vedolizumab
- Strength
- 108 mg/.68mL
- Form
- Injection, Solution
- Class
- Integrin Receptor Antagonist
Takeda Pharmaceuticals America, Inc.
Not stocked by us — reference only
vedolizumab
Listed by Takeda Pharmaceuticals America, Inc.
| Dosage form | Injection, Powder, Lyophilized, For Solution |
|---|---|
| Route | Intravenous |
| Drug class | Integrin Receptor Antagonist |
| Approval route | BLA — biologic licence |
| NDC code | 64764-300 |
| FDA application | BLA125476 |
| RxNorm concept | 1538137 |
| Package sizes listed | 1 |
| Marketed since | May 2014 |
Same active ingredient, different manufacturer, strength or form. Products matching on both ingredient and strength are usually interchangeable — but confirm before switching, especially with modified-release forms.
vedolizumab
Takeda Pharmaceuticals America, Inc.
Not stocked by us — reference only
vedolizumab
Takeda Pharmaceuticals America, Inc.
Not stocked by us — reference only
Information only, not medical advice. Nothing on this page indicates that a medication is safe or suitable for you. Speak to a prescriber or pharmacist before starting, stopping or switching any medicine.
Please don't share card details in chat.